Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Medical Genetics, |
RCV000735439 | SCV000853288 | pathogenic | Char syndrome | 2017-11-14 | criteria provided, single submitter | clinical testing | Char syndrome is caused by a genetic mutation in the transcription factor AP-2 Beta (TFAP2B) gene and follows an autosomal dominant mode of inheritance. Complete penetrance and variable expression have been reported. Various animal experimental studies showed that the TFAP2B gene product plays a critical role in the remodeling of the patent ductus arteriosus (PDA) as well as limb patterning. Most reported pathogenic variants in TFAP2B gene are missense mutations in the coding region, affecting the basic domain that is critical for DNA binding. Other reported mutations are intronic point mutations that alter splicing, or frameshift deletions. In this study we report a child with a novel heterozygous TFAP2B mutation c.650delG p.(Gly217Alafs*32), occurring de novo. |